Skip to main content
News Schmidt 01.2021
Paul Albert König (left) and Florian Ingo Schmidt (right)
© Volker Lannert / Uni Bonn

News categories: Publication

New promising antibodies against SARS-CoV-2

ImmunoSensation2 member Florian I. Schmidt together with Paul-Albert König, head of the Nanobody Core Facility and an international team have identified and further developed novel antibody fragments against the SARS coronavirus-2.

These "nanobodies" are much smaller than the classic antibodies used to treat SARS-CoV-2 infections, for example. They therefore penetrate the tissue better and can be produced more easily in larger quantities. The researchers at the University Hospital Bonn have also combined the nanobodies into potentially particularly effective molecules. These attack different parts of the virus simultaneously. The approach could prevent the pathogen from evading the active agent through mutations. The results are published in the journal Science.

"We focus on another group of molecules, the nanobodies," explains Dr. Florian Schmidt, who heads an Emmy Noether group on this promising new field of research at the University of Bonn's Institute of Innate Immunity. "Nanobodies are antibody fragments that are so simple that they can be produced by bacteria or yeast, which is less expensive."

The researchers also exploit another major advantage of nanobodies over antibodies: Their simple structure allows straight forward combinations to form molecules that can be several hundred times more effective. "We have fused two nanobodies that target different parts of the spike protein," explains König. "This variant was highly effective in cell culture. Furthermore, we were able to show that this drastically reduces the probability of the virus to become resistant to the active agent through escape mutations." The researchers are convinced that the molecules may be developed into a novel and promising therapeutic option.

Dioscure Therapeutics, a spin-off of the University of Bonn, will test the nanobodies in clinical studies. The success of the project is mainly based on the excellent cooperation of the participating research groups at the University with national and international cooperation partners, emphasizes Florian Schmidt.


Publication

Paul-Albert König, Hrishikesh Das, Hejun Liu, Beate M. Kümmerer, Florian N. Gohr, Lea-Marie Jenster, Yonas M. Tesfamariam, Lisa D.J. Schiffelers, Miki Uchima, Jennifer D. Wuerth, Karl Gatterdam, Natalia Ruetalo, Maria H. Christensen, Caroline I. Fandrey, Sabine Normann, Steffen Pritzl, Jan M. P. Tödtmann, Leo Hanke, Jannik Boos, Meng Yuan, Xueyong Zhu, Jonathan Leo Schmid-Burgk, Hiroki Kato, Michael Schindler, Ian A. Wilson, Matthias Geyer, Kerstin U. Ludwig, B. Martin Hällberg, Nicholas C. Wu and Florian I. Schmidt: Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape. Science; DOI: 10.1126/science.abe6230


Contact

Dr. Florian I. Schmidt

Institute of Innate Immunity

University Hospital Bonn

University of Bonn

Email: fschmidt@uni-bonn.de

Phone office: +49-228/287-51124

Phone lab: +49-228/287-54708

Cell: +49-176/70021810

Related news

20240523 PM  Hoelzel Herrlinger Layer 1212 wp header

News categories: Publication

Novel RNA therapy is effective against highly aggressive brain tumors

The findings of the GLORIA study were published in "Nature Communications"
View entry
20240506 PM Hoerauf Achim 2048x854px

News categories: Publication

New antibiotic against river blindness and lymphatic filariasis pathogens

Japanese fund supports research into the treatment of filarial infections at University Hospital Bonn.
View entry
20240321 PM PM Klumper 010

News categories: Publication

Bonn scientists predict the connection between biomarker expression and long-term survival in patients with urothelial cancer

PD Dr. Niklas Klümper and Prof. Michael Hölzel discovered that NECTIN4 amplifications are genomic predictors of long-term survival in patients suffering from metastatic urothelial cancer (mUC). Their findings were published in the latest edition of the “Journal of Clinical Oncology”.
View entry

Back to the news overview